Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Arrowhead Pharma (NQ: ARWR)
13.87 USD  +0.72 (+5.48%)
Official Closing Price  /  Updated: 5:14 PM EDT, Oct 16, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,316,835
Open 13.04
Bid (Size) 13.55 (1)
Ask (Size) 14.00 (10)
Prev. Close 13.15
Today's Range 13.00 - 14.00
52wk Range 3.010 - 22.39
Shares Outstanding 87,577,188
Dividend Yield N/A
Performance
YTD
+272.85%
+272.85%
1 Month
-23.83%
-23.83%
3 Month
-12.22%
-12.22%
6 Month
+102.78%
+102.78%
1 Year
+256.56%
+256.56%
Top News
More News
Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
Arrowhead hosts R&D Day to discuss its emerging pipeline of RNAi therapeutics that leverage the Targeted RNAi Molecule (TRiM™) platform Read More
from Business Wire News Releases
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Arrowhead filed an application to begin a Phase 1 clinical trial of ARO-ANG3, RNAi-based investigational medicine for the treatment of dyslipidemias. Read More
from Business Wire News Releases
More News
Read More
Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
from Business Wire News Releases
Johnson & Johnson is set to report earnings before the bell — here's what the Street expects
category Johnson & Johnson , Health care industry , Biotechnology , and 8 more.
from CNBC.com News
Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
from Business Wire News Releases
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
from Business Wire News Releases
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
from Business Wire News Releases
Implied TUSA Analyst Target Price: $40
category ETFs
from ETF Channel
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
from Business Wire News Releases
This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging
category ARWR , Market News , JNJ
from Motley Fool
Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'
category Benzinga , Janssen Pharmaceuticals , Piper Jaffray , and 16 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X